~~**CLAIMS**~~

Claims

1.~~-~~ A swallowable film coated tablet ~~for oral administration~~ which contains deferasirox~~ or a pharmaceutically acceptable salt thereof~~ present in an amount of from 45% to 60% by weight based on the total weight of the tablet, and wherein the tablet contains 90 mg, 180 mg or 360 mg of deferasirox~~ or a pharmaceutically acceptable salt thereof,~~ , wherein deferasirox is present in free acid form,

wherein the tablet further comprises,

(i) at least one filler in a total amount of 10% to 40 % by weight based on total weight of the tablet, wherein the filler is microcrystalline cellulose;

(ii) at least one disintegrant in a total amount of 1% to 10% by weight based on the total weight of the tablet, wherein the disintegrant is cross-linked polyvinylpyrrolidone (crospovidone);

(iii) at least one binder in a total amount of 1% to 5% by weight based on the total weight of the tablet, wherein the binder is polyvinylpyrrolidone (PVP);

(iv) at least one surfactant in a total amount of ~~0.0%~~up to 2% by weight based on the total weight of the tablet, wherein the surfactant is poloxamer;

(v) at least one glidant in a total amount of 0.1% to 1% by weight based on the total weight of the tablet, wherein the glidant is colloidal silicon dioxide;

(vi) at least one lubricant in a total amount of ~~less than~~ 0.1% to 2% by weight based on the total weight of the tablet, wherein the lubricant is magnesium stearate; and

(vii) ~~optionally,~~ a coating~~.~~

and wherein the tablet does not contain sodium lauryl sulfate and does not contain lactose.

2.~~-~~ The swallowable film coated tablet ~~for oral administration~~ according to claim 1, wherein the tablet contains 90 mg of deferasirox~~ or a pharmaceutically acceptable salt thereof.~~.

3.~~-~~ The swallowable film coated tablet ~~for oral administration~~ according to claim 1, wherein the tablet contains 180 mg of deferasirox~~ or a pharmaceutically acceptable salt thereof.~~.

4.~~-~~ The swallowable film coated tablet ~~for oral administration~~ according to claim 1, wherein the tablet contains 360 mg of deferasirox~~ or a pharmaceutically acceptable salt thereof.~~
.

~~5. The tablet for oral administration according to any one of the preceding claims, wherein the tablet exhibits a disintegration time of 5-10 minutes when measured by a standard USP disintegration test.~~

~~6. A tablet for oral administration consisting of~~ ~~90 mg deferasirox;~~
~~53.61 mg microcrystalline cellulose;~~
~~3.65 mg polyvinylpyrrolidone;~~
~~11.34 mg crospovidone;~~
~~0.16 mg poloxamer;~~
~~0.81 mg colloidal silica;~~
~~2.43 mg magnesium stearate; and~~
~~optionally, 4.86 mg coating.~~

~~7. A tablet for oral administration consisting of~~ ~~180 mg deferasirox;~~
~~107.23 mg microcrystalline cellulose;~~
~~7.29 mg polyvinylpyrrolidone;~~
~~22.68 mg crospovidone;~~
~~0.32 mg poloxamer;~~
~~1.62 mg colloidal silica;~~
~~4.86 mg magnesium stearate; and~~
~~optionally, 9.72 mg coating.~~

~~8. A tablet for oral administration consisting of~~ ~~360 mg deferasirox;~~
~~215.45 mg microcrystalline cellulose;~~
~~14.58 mg polyvinylpyrrolidone;~~
~~45.36 mg crospovidone;~~
~~0.65 mg poloxamer;~~
~~3.24 mg colloidal silica;~~
~~9.72 mg magnesium stearate; and~~
~~optionally, 19.44 mg coating.~~